Cargando…
Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV inf...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897528/ https://www.ncbi.nlm.nih.gov/pubmed/31805031 http://dx.doi.org/10.15585/mmwr.mm6848e1 |
_version_ | 1783476975208235008 |
---|---|
author | Harris, Norma S. Johnson, Anna Satcher Huang, Ya-Lin A. Kern, Dayle Fulton, Paul Smith, Dawn K. Valleroy, Linda A. Hall, H. Irene |
author_facet | Harris, Norma S. Johnson, Anna Satcher Huang, Ya-Lin A. Kern, Dayle Fulton, Paul Smith, Dawn K. Valleroy, Linda A. Hall, H. Irene |
author_sort | Harris, Norma S. |
collection | PubMed |
description | BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV infection) and seeks to leverage testing, treatment, and preexposure prophylaxis (PrEP) to reduce new HIV infections in the United States by at least 90% by 2030. Targets to reach this goal include that at least 95% of persons with HIV receive a diagnosis, 95% of persons with diagnosed HIV infection have a suppressed viral load, and 50% of those at increased risk for acquiring HIV are prescribed PrEP. Using surveillance, pharmacy, and other data, CDC determined the current status of these three initiative strategies. METHODS: CDC analyzed HIV surveillance data to estimate annual number of new HIV infections (2013–2017); estimate the percentage of infections that were diagnosed (2017); and determine the percentage of persons with diagnosed HIV infection with viral load suppression (2017). CDC analyzed surveillance, pharmacy, and other data to estimate PrEP coverage, reported as a percentage and calculated as the number of persons who were prescribed PrEP divided by the estimated number of persons with indications for PrEP. RESULTS: The number of new HIV infections remained stable from 2013 (38,500) to 2017 (37,500) (p = 0.448). In 2017, an estimated 85.8% of infections were diagnosed. Among 854,206 persons with diagnosed HIV infection in 42 jurisdictions with complete reporting of laboratory data, 62.7% had a suppressed viral load. Among an estimated 1.2 million persons with indications for use of PrEP, 18.1% had been prescribed PrEP in 2018. CONCLUSION: Accelerated efforts to diagnose, treat, and prevent HIV infection are needed to achieve the U.S. goal of at least 90% reduction in the number of new HIV infections by 2030. |
format | Online Article Text |
id | pubmed-6897528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-68975282019-12-12 Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 Harris, Norma S. Johnson, Anna Satcher Huang, Ya-Lin A. Kern, Dayle Fulton, Paul Smith, Dawn K. Valleroy, Linda A. Hall, H. Irene MMWR Morb Mortal Wkly Rep Vital Signs BACKGROUND: Approximately 38,000 new human immunodeficiency virus (HIV) infections occur in the United States each year; these infections can be prevented. A proposed national initiative, Ending the HIV Epidemic: A Plan for America, incorporates three strategies (diagnose, treat, and prevent HIV infection) and seeks to leverage testing, treatment, and preexposure prophylaxis (PrEP) to reduce new HIV infections in the United States by at least 90% by 2030. Targets to reach this goal include that at least 95% of persons with HIV receive a diagnosis, 95% of persons with diagnosed HIV infection have a suppressed viral load, and 50% of those at increased risk for acquiring HIV are prescribed PrEP. Using surveillance, pharmacy, and other data, CDC determined the current status of these three initiative strategies. METHODS: CDC analyzed HIV surveillance data to estimate annual number of new HIV infections (2013–2017); estimate the percentage of infections that were diagnosed (2017); and determine the percentage of persons with diagnosed HIV infection with viral load suppression (2017). CDC analyzed surveillance, pharmacy, and other data to estimate PrEP coverage, reported as a percentage and calculated as the number of persons who were prescribed PrEP divided by the estimated number of persons with indications for PrEP. RESULTS: The number of new HIV infections remained stable from 2013 (38,500) to 2017 (37,500) (p = 0.448). In 2017, an estimated 85.8% of infections were diagnosed. Among 854,206 persons with diagnosed HIV infection in 42 jurisdictions with complete reporting of laboratory data, 62.7% had a suppressed viral load. Among an estimated 1.2 million persons with indications for use of PrEP, 18.1% had been prescribed PrEP in 2018. CONCLUSION: Accelerated efforts to diagnose, treat, and prevent HIV infection are needed to achieve the U.S. goal of at least 90% reduction in the number of new HIV infections by 2030. Centers for Disease Control and Prevention 2019-12-06 /pmc/articles/PMC6897528/ /pubmed/31805031 http://dx.doi.org/10.15585/mmwr.mm6848e1 Text en https://creativecommons.org/licenses/by/3.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
spellingShingle | Vital Signs Harris, Norma S. Johnson, Anna Satcher Huang, Ya-Lin A. Kern, Dayle Fulton, Paul Smith, Dawn K. Valleroy, Linda A. Hall, H. Irene Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 |
title | Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 |
title_full | Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 |
title_fullStr | Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 |
title_full_unstemmed | Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 |
title_short | Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018 |
title_sort | vital signs: status of human immunodeficiency virus testing, viral suppression, and hiv preexposure prophylaxis — united states, 2013–2018 |
topic | Vital Signs |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897528/ https://www.ncbi.nlm.nih.gov/pubmed/31805031 http://dx.doi.org/10.15585/mmwr.mm6848e1 |
work_keys_str_mv | AT harrisnormas vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT johnsonannasatcher vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT huangyalina vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT kerndayle vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT fultonpaul vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT smithdawnk vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT valleroylindaa vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 AT hallhirene vitalsignsstatusofhumanimmunodeficiencyvirustestingviralsuppressionandhivpreexposureprophylaxisunitedstates20132018 |